|
Orthologous residues
|
|
Smc1 (human): S966‑p, Smc1 (mouse): S966‑p, Smc1 (rat): S966‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Disease tissue studied:
ataxia-telangiectasic cancer
|
|
Relevant cell lines - cell types - tissues:
AG1522 (fibroblast), SKNSH (neural crest)
|
|
Cellular systems studied:
primary cultured cells
|
|
Species studied:
human
|
|
Comments:
AT5BI fibroblasts were derived from a patient with ataxia telangiectasia.
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATM (human)
|
|
Cells from ataxia telangiectasia patients, deficient in ATM activity, failed to phosphorylate S966 after ionizing radiation.
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
|
Associated Diseases
|
|
Diseases:
|
Alterations:
|
Comments:
|
|
ataxia-telangiectasic cancer
|
decreased
|
|
|